InterMune (ITMN) Announces Quarterly Earnings, Beats Estimates By $0.10 EPS
InterMune (NASDAQ:ITMN) released its earnings data on Wednesday. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.10, Analyst Ratings Net reports. The company had revenue of $19.72 million for the quarter, compared to the consensus estimate of $16.44 million. During the same quarter in the previous year, the company posted ($0.63) earnings per share. The company’s revenue for the quarter was up 161.9% on a year-over-year basis.
A number of analysts have recently weighed in on ITMN shares. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of InterMune in a research note to investors on Wednesday, September 18th. They now have a $17.00 price target on the stock. Analysts at Goldman Sachs Group Inc. raised their price target on shares of InterMune from $11.00 to $12.00 in a research note to investors on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $16.75.
InterMune (NASDAQ:ITMN) traded down 4.33% during mid-day trading on Wednesday, hitting $13.26. The stock had a trading volume of 855,233 shares. InterMune has a 52 week low of $7.23 and a 52 week high of $16.00. The stock’s 50-day moving average is $14.83 and its 200-day moving average is $11.09. The company’s market cap is $1.087 billion.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.